News
INAB
0.7580
-1.86%
-0.0144
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 4d ago
Analysts Are Bullish on Top Healthcare Stocks: PepGen Inc. (PEPG), IN8bio (INAB)
TipRanks · 4d ago
IN8bio announces updated clinical data from INB-200, INB-400 programs
TipRanks · 4d ago
IN8bio Presents Updated Clinical Data From INB-200 And INB-400 Programs In Newly Diagnosed GBM, In Oral Session At 2026 SNO Annual Meeting
Benzinga · 4d ago
Weekly Report: what happened at INAB last week (1109-1113)?
Weekly Report · 4d ago
Weekly Report: what happened at INAB last week (1102-1106)?
Weekly Report · 11/09 10:25
In8bio, Inc. Confronts Rising Social Media, AI, and Cyber Risk to Reputation and Competitive Edge
TipRanks · 11/07 06:02
IN8bio: Buy Rating Reiterated with $5 Price Target Unchanged on Promising Oncology Pipeline
TipRanks · 11/07 00:15
Weekly Report: what happened at INAB last week (1026-1030)?
Weekly Report · 11/02 10:25
Weekly Report: what happened at INAB last week (1019-1023)?
Weekly Report · 10/26 10:24
Weekly Report: what happened at INAB last week (1012-1016)?
Weekly Report · 10/19 10:24
Weekly Report: what happened at INAB last week (1005-1009)?
Weekly Report · 10/12 10:30
Press Release: IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 10/06 20:00
Weekly Report: what happened at INAB last week (0928-1002)?
Weekly Report · 10/05 10:30
IN8bio Consensus Price Target Raised 12% to $7.14
NASDAQ · 10/03 01:15
H.C. Wainwright Remains a Buy on IN8bio (INAB)
TipRanks · 10/01 14:25
Weekly Report: what happened at INAB last week (0921-0925)?
Weekly Report · 09/28 10:24
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 09/24 21:05
Analysts’ Top Healthcare Picks: IN8bio (INAB), Daré Bioscience (DARE)
TipRanks · 09/22 10:00
Weekly Report: what happened at INAB last week (0914-0918)?
Weekly Report · 09/21 10:24
More
Webull provides a variety of real-time INAB stock news. You can receive the latest news about In8Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About INAB
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.